Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Marsden Eye Specialists Parramatta /ID# 232761
Paramatta, New South Wales, Australia
Melbourne Eye Specialists /ID# 232767
Fitzroy, Victoria, Australia
Eye Surgery Associates P/L ATF Eye Surgery Associates Unit Trust /ID# 232765
Vermont South, Victoria, Australia
Institut de loeil des Laurentides /ID# 232780
Boisbriand, Quebec, Canada
Ophthalmology Clinic Bellevue /ID# 232782
Montreal, Quebec, Canada
Prism Eye Institute /ID# 232917
Mississauga, Canada
Nuh Medical Centre /ID# 232905
Singapore, Singapore
Tan Tock Seng Hospital /ID# 233014
Singapore, Singapore
Seoul National University Hospital /ID# 233099
Seoul, South Korea
Buddhist Tzu Chi General Hospital /ID# 232664
Hualien City, Hualien, Taiwan
Start Date
July 19, 2018
Primary Completion Date
March 18, 2022
Completion Date
March 18, 2022
Last Updated
May 17, 2023
65
ACTUAL participants
XEN45
DEVICE
Lead Sponsor
Allergan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07396441